These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 30083516)
21. NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells. Sobhakumari A; Schickling BM; Love-Homan L; Raeburn A; Fletcher EV; Case AJ; Domann FE; Miller FJ; Simons AL Toxicol Appl Pharmacol; 2013 Nov; 272(3):736-45. PubMed ID: 23917044 [TBL] [Abstract][Full Text] [Related]
22. EGFR tyrosine kinase inhibitors differentially affect autophagy in head and neck squamous cell carcinoma. Cai J; Sun M; Ge X; Sun Y Biochem Biophys Res Commun; 2017 May; 486(4):1027-1033. PubMed ID: 28366635 [TBL] [Abstract][Full Text] [Related]
23. PET monitoring of therapy response in head and neck squamous cell carcinoma. Schöder H; Fury M; Lee N; Kraus D J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408 [TBL] [Abstract][Full Text] [Related]
24. Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET. Jansen JF; Schöder H; Lee NY; Stambuk HE; Wang Y; Fury MG; Patel SG; Pfister DG; Shah JP; Koutcher JA; Shukla-Dave A Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):299-307. PubMed ID: 21236594 [TBL] [Abstract][Full Text] [Related]
25. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma. Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738 [TBL] [Abstract][Full Text] [Related]
26. Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma. Stanam A; Love-Homan L; Joseph TS; Espinosa-Cotton M; Simons AL Mol Oncol; 2015 Aug; 9(7):1371-83. PubMed ID: 25888065 [TBL] [Abstract][Full Text] [Related]
27. Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI. Dirix P; Vandecaveye V; De Keyzer F; Stroobants S; Hermans R; Nuyts S J Nucl Med; 2009 Jul; 50(7):1020-7. PubMed ID: 19525447 [TBL] [Abstract][Full Text] [Related]
28. Targeting IL-6/STAT3 signaling abrogates EGFR-TKI resistance through inhibiting Beclin-1 dependent autophagy in HNSCC. Wang Y; Zhou Q; Liu C; Zhang R; Xing B; Du J; Dong L; Zheng J; Chen Z; Sun M; Yao X; Ren Y; Zhou X Cancer Lett; 2024 Apr; 586():216612. PubMed ID: 38211653 [TBL] [Abstract][Full Text] [Related]
30. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models. Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485 [TBL] [Abstract][Full Text] [Related]
31. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc. Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101 [TBL] [Abstract][Full Text] [Related]
32. Growth factor expression mediates resistance to EGFR inhibitors in head and neck squamous cell carcinomas. Tepper SR; Zuo Z; Khattri A; Heß J; Seiwert TY Oral Oncol; 2016 May; 56():62-70. PubMed ID: 27086488 [TBL] [Abstract][Full Text] [Related]
33. Enhanced response of human head and neck cancer xenograft tumors to cisplatin combined with 2-deoxy-D-glucose correlates with increased 18F-FDG uptake as determined by PET imaging. Simons AL; Fath MA; Mattson DM; Smith BJ; Walsh SA; Graham MM; Hichwa RD; Buatti JM; Dornfeld K; Spitz DR Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1222-30. PubMed ID: 17967311 [TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor signaling in precancerous keratinocytes promotes neighboring head and neck cancer squamous cell carcinoma cancer stem cell-like properties and phosphoinositide 3-kinase inhibitor insensitivity. Nguyen KA; Keith MJ; Keysar SB; Hall SC; Bimali A; Jimeno A; Wang XJ; Young CD Mol Carcinog; 2022 Jul; 61(7):664-676. PubMed ID: 35417043 [TBL] [Abstract][Full Text] [Related]
35. Multiparametric functional MRI and Martens RM; Koopman T; Lavini C; Ali M; Peeters CFW; Noij DP; Zwezerijnen G; Marcus JT; Vergeer MR; Leemans CR; de Bree R; de Graaf P; Boellaard R; Castelijns JA Eur Radiol; 2021 Feb; 31(2):616-628. PubMed ID: 32851444 [TBL] [Abstract][Full Text] [Related]
36. ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer. Bill A; Gutierrez A; Kulkarni S; Kemp C; Bonenfant D; Voshol H; Duvvuri U; Gaither LA Oncotarget; 2015 Apr; 6(11):9173-88. PubMed ID: 25823819 [TBL] [Abstract][Full Text] [Related]
37. PET Imaging in Head and Neck Cancer Patients to Monitor Treatment Response: A Future Role for EGFR-Targeted Imaging. van Dijk LK; Boerman OC; Kaanders JH; Bussink J Clin Cancer Res; 2015 Aug; 21(16):3602-9. PubMed ID: 25931452 [TBL] [Abstract][Full Text] [Related]
38. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma. Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733 [TBL] [Abstract][Full Text] [Related]